Why Vaxart Stock Slumped Today

What happened

Shares of Vaxart (NASDAQ: VXRT), a clinical-stage biotech focused on the development of orally administered vaccines, were down by 10.7% on Tuesday. The market is responding to the company's corporate update, which previewed Vaxart's financial results for the first quarter. 

So what

In its corporate update, the company said it expects to release additional data "within days" on its pre-clinical trial testing several potential COVID-19 vaccines. Vaxart had previously released preliminary data for this trial, noting that several of its investigational vaccines for the coronavirus had generated immune responses in all tested animals after a single dose.

Nurse filling up a syringe with liquid from a glass vial.

Image source: Getty Images.

With that said, the little first-quarter financial data that Vaxart shared in its corporate update was a bit of a mixed bag. The company reported that its cash balance at the end of the quarter was $29.9 million, a 256% year-over-year increase. But revenue of $2.8 million plunged by about 48% compared with the first quarter of the previous fiscal year. Vaxart's double-digit losses on the stock market today can likely be attributed to its disappointing revenue for the first quarter of 2020.

Now what

Vaxart's stock is still up by more than 800% year to date. With the company racing to develop a vaccine for COVID-19, investors are hopeful that it will make a fortune off of it, and reward its shareholders in the process. Whether the biotech company can pull that off, however, remains highly unlikely. With no approved products on the market and an inflated stock price due to the faint hope that it will manage to win the race to market a COVID-19 vaccine, Vaxart doesn't look particularly attractive at the moment. 

10 stocks we like better than Vaxart, Inc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Vaxart, Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of April 16, 2020


Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More